Michael Celano - 26 Jan 2026 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role: Chief Financial Officer
Signature: /s/ Jennifer Johansson, Attorney-in-fact
Issuer symbol: LRMR
Transactions as of: 26 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 27 Jan 2026, 17:03:39 UTC
Previous filing: 24 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Celano Michael	Chief Financial Officer	C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST, SUITE 506, BALA CYNWYD	/s/ Jennifer Johansson, Attorney-in-fact	27 Jan 2026	0001377582

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LRMR	Common Stock	Award	$0	+37,604	+21%	$0.000000	215,785	26 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LRMR	Stock Option (Right to Buy)	Award	$0	+225,622		$0.000000	225,622	26 Jan 2026	Common Stock	225,622	$3.60	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2	The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.